Neoantigen quality, not quantity

Nicholas McGranahan^{1

2}, Charles Swanton^{1

3}

Affiliations

¹ Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK. nicholas.mcgranahan.10@ucl.ac.uk charles.swanton@crick.ac.uk.
² Cancer Genome Evolution Research Group, University College London Cancer Institute, University College London, London WC1E 6BT, UK.
³ Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Review

Nicholas McGranahan et al. Sci Transl Med. 2019.

. 2019 Aug 21;11(506):eaax7918.

doi: 10.1126/scitranslmed.aax7918.

Nicholas McGranahan^{1

2}, Charles Swanton^{1

3}

¹ Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK. nicholas.mcgranahan.10@ucl.ac.uk charles.swanton@crick.ac.uk.
² Cancer Genome Evolution Research Group, University College London Cancer Institute, University College London, London WC1E 6BT, UK.
³ Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Abstract

Prioritizing expressed clonal neoantigens in genes required for cancer cell survival may reduce the likelihood of resistance to neoantigen therapies.